2019：全球乙肝药物研发管线（HBV Pipeline）
2019-05-15 不详 网络
正大天晴（TLR7激动剂-强生）、恒瑞医药（TLR-7）、齐鲁制药、东阳光药、挚盟医药、歌礼药业、亚盛医药、贺普生物等等。
中国药企在做乙肝药物的有：
正大天晴（TLR7激动剂-强生）、恒瑞医药（TLR-7）、齐鲁制药、东阳光药、挚盟医药、歌礼药业、亚盛医药、贺普生物等等。
下边来自HBV基金会，仅供参考：
|
FAMILY/DRUG NAME(药物名称)
|
MECHANISM （药物机制） |
COMPANY （公司） |
WEBSITE （网站） |
USA STATUS |
|
Interferons: Mimic infection-fighting immune substances naturally produced in the body. |
||||
|
Intron A (Interferon alfa-2b) |
Immunomodulator |
Merck, USA |
merck.com |
Approved 1991 |
|
Pegasys (Peginterferon alfa-2a) |
Immunomodulator |
Genentech, USA |
gene.com |
Approved 2005 |
|
|
||||
|
Epivir (Lamivudine) |
Inhibits viral DNA polymerase |
GlaxoSmithKline (GSK) |
gsk.com |
Approved 1998 |
|
Hepsera (Adefovir dipivoxil) |
Inhibits viral DNA polymerase |
Gilead Sciences, USA |
gilead.com |
Approved 2002 |
|
Baraclude (Entecavir) |
Inhibits viral DNA polymerase |
Bristol-Myers Squibb, USA |
bms.com |
Approved 2005 |
|
Tyzeka (Telbivudine) |
Inhibits viral DNA polymerase |
Novartis, USA |
novartis.com |
Approved 2006 |
|
Viread (Tenofovir) |
Inhibits viral DNA polymerase |
Gilead Sciences |
gilead.com |
Approved 2008 |
|
Vemlidy (TAF or tenofovir alafenamide) |
Prodrug of tenofovir |
Gilead Sciences |
gilead.com |
Approved 2016 |
|
Levovir (Clevudine) |
Inhibits viral DNA polymerase |
Bukwang, S. Korea |
bukwang.co.kr |
Approved 2006 in S. Korea |
|
Besivo (formerly ANA 380/LB80380) |
Inhibits viral DNA polymerase |
Ildong Pharma, S. Korea |
ildong.com/en |
Approved 2017 in S. Korea |
|
Zadaxin |
Immunomodulator |
SciClone, USA |
sciclone.com |
Approved outside USA |
|
DIRECT ACTING ANTIVIRALS: Targets the virus and interferes in the HBV replication process |
||||
|
TDF Pro Drugs: A modified tenofovir drug that can get into liver cells more easily |
||||
|
TXL (CMX 157) |
Prodrug of tenofovir |
ContraVir, USA
|
contravir.com |
Phase II |
|
Silencing RNA’s (siRNAs): Interferes and destroys viral RNA |
||||
|
ARB-1467 |
RNAi gene silencer (1.0) |
Arbutus Biopharma, USA |
arbutusbio.com |
Phase II |
|
RG6004 |
RNAi gene silencer |
Roche, Switzerland |
roche.com |
Phase I/II |
|
ARO-HBV |
RNAi gene silencer |
Arrowhead Pharma, USA |
arrowheadpharma.com |
Phase I/II |
|
AB-729 |
RNAi gene silencer |
Arbutus Biopharma, USA |
arbutusbio.com |
Phase I |
|
Vir-2218 |
RNAi gene silencer |
Alnylam and Vir Biotech, USA |
alnylam.com |
Phase I/II |
|
DCR-HBVS |
RNAi gene silencer |
Dicerna, USA |
dicerna.com |
Phase I |
|
BB-103 |
RNAi gene silencer |
Benitec, Australia |
benitec.com |
Preclinical |
|
Lunar-HBV |
RNAi gene silencer |
Arcturus, USA with Janssen |
arcturusrx.com |
Preclinical |
|
Entry Inhibitors: Interferes with HBV getting into liver cells |
||||
|
Myrcludex B |
Entry inhibitor |
Hepatera, Russia with MYR GmbH, Germany |
myr-pharma.com |
Phase IIb |
|
Capsid Inhibitors: Interferes with the viral DNA protein shield |
||||
|
Morphothiadin (GLS4) |
Capsid inhibitor |
HEC Pharma, |
pharm.hec.cn/en |
Phase II |
|
JNJ 56136379 |
Capsid inhibitor |
Janssen, Scotland |
janssen.com |
Phase II |
|
ABI-H0731 |
Capsid inhibitor |
Assembly Biosciences, USA |
assemblybio.com |
Phase II |
|
AB-423 |
Capsid inhibitor |
Arbutus Biopharma, USA |
arbutusbio.com |
Phase I |
|
AB-506 |
Capsid inhibitor |
Arbutus Biopharma, USA |
arbutusbio.com/ |
Phase I |
|
ABI-H2158 |
Capsid inhibitor |
Assembly Biosciences, USA |
assemblybio.com |
Phase I |
|
RG7907 |
Capsid inhibitor |
Roche, Switzerland |
roche.com |
Phase I |
|
QL-007 |
Capsid inhibitor |
Qilu, China（齐鲁） |
qilu-pharma.com |
Phase I |
|
GLP-26 |
Capsid inhibitor |
Emory University |
emory.edu |
Preclinical |
|
EP-027367 |
Capsid inhibitor |
Enanta Pharmaceuticals, USA |
enanta.com |
Preclinical |
|
QL-0A6a |
Capsid inhibitor |
Qilu, China |
qilu-pharma.com |
Preclinical |
|
CB-HBV-001 |
Capsid inhibitor |
ZhiMeng Biopharma, China（挚盟医药） |
core-biopharma.com |
Preclinical |
|
HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg) |
||||
|
REP 2139 |
sAg inhibitor |
Replicor, Canada |
replicor.com |
Phase II |
|
REP 2165 |
sAg inhibitor |
Replicor, Canada |
replicor.com |
Phase II |
|
Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein |
||||
|
IONIS-HBVRx (GSK3228836) |
Viral protein inhibitor |
Ionis Pharma, USA with GSK |
ionispharma.com |
Phase II |
|
IONIS-HBVLRx (GSK33389404) |
Viral protein inhibitor |
Ionis Pharma with GSK |
ionispharma.com |
Phase II |
|
|
||||
|
ARB-452 |
Viral RNase Inhibitor |
Arbutus Biopharma, USA |
arbutusbio.com |
Preclinical |
|
INDIRECT ACTING ANTIVIRALS: Targets the human immune system to attack the HBV virus |
||||
|
Therapeutic Vaccines: Vaccine technology used to stimulate the immune system as a treatment |
||||
|
ABX203 |
Therapeutic vaccine |
Center for Genetic Engineering and Biotechnology, Cuba |
cigb.edu.cu/en |
Phase III |
|
AIC 649 |
Therapeutic vaccine |
AiCuris, Germany |
aicuris.com |
Phase I |
|
INO-1800 |
Therapeutic vaccine |
Inovio, USA |
inovio.com |
Phase I |
|
HB-110 |
Therapeutic vaccine |
Ichor Medical Systems with Janssen, USA |
ichorms.com |
Phase I |
|
TG1050 |
Therapeutic vaccine |
Transgene, France |
transgene.com |
Phase I |
|
HepTcell |
Therapeutic vaccine |
Altimmune, USA |
altimmune.com |
Phase I |
|
HBV (TomegaVax) |
Therapeutic vaccine |
TomegaVax, USA |
tomegavax.com |
Preclinical |
|
HBV |
Therapeutic vaccine |
GeoVax Labs, USA |
geovax.com |
Preclinical |
|
VR-CHB01 |
Therapeutic vaccine |
Vical, USA |
vical.com |
Preclinical |
|
VBI-2601 |
Therapeutic vaccine |
VBI Vaccines, USA with Brii Biosciences |
vbivaccines.com |
Preclinical |
|
Chimigen HBV |
Therapeutic vaccine |
Akshaya Bio Inc., Canada |
akshayabio.com |
Preclinical |
|
CARG-201 |
Therapeutic vaccine |
CaroGen Crop |
carogencorp.com |
Preclinical |
|
Innate Immune Defense Pathway: Compounds that activate the innate immune system |
||||
|
RG7795 |
TLR-7 agonist |
Roche, Switzerland |
roche.com |
Phase II |
|
Inarigivir (SB9200) |
RIG -1 and NOD2 agonist |
Spring Bank Pharmaceuticals, USA |
springbankpharm.com |
Phase II |
|
GS9688 |
TLR-8 agonist |
Gilead Sciences, USA |
gilead.com |
Phase I |
|
RG7854 |
TLR-7 agonist |
Roche, Switzerland |
roche.com |
Phase I |
|
Host Acting Pathway: Compounds that induce programmed cell death (apoptosis) |
||||
|
APG-1387 |
Apoptosis Inducer |
Ascentage Pharma, China（亚盛） |
en.ascentagepharma.com |
Phase I |
|
CRV 431 (CPI 431-32) |
Ciclofillin inhibitor |
ContraVir, USA |
contravir.com |
Preclinical |
|
Gene Editing |
||||
|
EBT106 |
CRISPR/Cas 9 |
Excision Biotherapeutics, USA |
www.excisionbio.com |
Preclinical |
|
HBV |
CRISPR/Cas 9 |
Intellia Therapeutics, USA |
intelliatx.com |
Preclinical |
|
HBV |
ARCUS |
Precision Biopharma, USA with Gilead |
precisionsciences.com |
Preclinical |
|
|
||||
|
GC1102 |
sAg monoclonal antibody |
Green Cross, South Korea |
www.globalgreencross.com |
Phase II |
|
EYP001 |
FXR agonist |
Enyo Pharma, France |
enyopharma.com |
Phase I |
|
LTCR-H2-1 |
T Cell immunotherapy |
Lion TCR, Singapore |
www.liontcr.com |
Preclinical |
|
IMMTav |
T Cell immunomodulator |
Immunocore, USA |
immunocore.com |
Preclinical |
|
HBV |
MicroRNA |
Regulus Therapeutics, USA |
regulusrx.com |
Preclinical |
|
HEPATITIS DELTA VIRUS (HDV) |
||||
|
Lambda (Pegylated Interferon) |
Immunomodulator |
Eiger Biopharma, USA |
eigerbio.com |
Orphan drug designation |
|
Myrcludex B |
Entry inhibitor |
MYR-GmbH, Germany |
myr-pharma.com |
Breakthrough Therapy Designation |
|
Lonafarnib |
Prenylation inhibitor |
Eiger Biopharma, USA |
eigerbio.com |
FDA Fast Track Designation |
|
REP 2139/ REP 2165 |
HBsAg inhibitor |
Replicor, Canada |
replicor.com |
Phase II |
|
Ezetimibe |
NTCP inhibitor |
Ziauddin University Hospital, Pakistan |
zu.edu.pk |
Phase II |
|
ALN-HDV |
RNAi gene silencer |
Alnylam, USA |
alnylam.com |
Preclinical |
|
GI-18000 |
Immune Response Stimulator |
GlobeImmune |
globeimmune.com |
Preclinical |
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#HBV#
63
#PE#
59
#研发#
62
#药物研发#
66
#PEL#
48